Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
MetadataShow full item record
CitationKesselheim, Aaron S., Carolyn L. Treasure, and Steven Joffe. 2017. “Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.” PLoS Medicine 14 (1): e1002190. doi:10.1371/journal.pmed.1002190. http://dx.doi.org/10.1371/journal.pmed.1002190.
AbstractAaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:30371184